Danaher Corporation
HealthcareNYSE:DHR · New York Stock Exchange
-$0.84 today
Vol 1.36M · Avg 4.59M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
6.9%
avg 10.1%
ROIC
5.7%
avg 6.1%
ROA
4.3%
avg 5.6%
Analysis
ROE is currently the strongest return metric at 6.9% versus its period average of 10.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Rainer Blair | President, Chief Executive Officer & Director | $6.12M | — | 62 | $47,475.00 | <0.01% |
Matthew R. McGrew | Executive Vice President | $3.17M | — | 54 | $26,825.00 | <0.01% |
Matthew E. Gugino | Chief Financial Officer & Executive Vice President | $2.70M | — | 43 | $26,825.00 | <0.01% |
Julie Sawyer Montgomery | Executive Vice President of Diagnostics Platform | $2.58M | — | 53 | $23,301.00 | <0.01% |
Christopher Paul Riley | Executive Vice President of Biotechnology Group & Chief Executive Officer of Cytiva | $2.54M | — | 52 | $9,337.00 | <0.01% |
Jose-Carlos Gutierrez-Ramos | Senior Vice President & Chief Science Officer | $2.52M | — | 64 | $19,018.00 | <0.01% |
Rachel Marie Vatnsdal Olson | Vice President of Investor Relations | — | — | — | — | — |
Mitchell Rales | Co-Founder & Director | — | — | 69 | $778,352.00 | 0.11% |
Steven Rales | Co-Founder & Chairman | — | — | 75 | $778,352.00 | 0.11% |
Martin Stumpe | Chief Technology & AI Officer | — | — | — | — | — |
Christopher Bouda | Vice President & Chief Accounting Officer | — | — | — | $9,337.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
18
$245.74M
Net Sentiment
$245.74M
Net selling
Most Active
RALES MITCHELL P
9 transactions
1–10 of 18
Analysis
Insiders reported 0 buys worth $0.00 and 18 sells worth $245.74M over the last 12 months. That adds up to net selling of $245.74M. RALES MITCHELL P was the most active insider with 9 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +12.2% | +6.1% (15yr)1 analysts |
| Revenue | N/A | N/A | -7.5% | +5.4% (15yr)7 analysts |
| Net Income | N/A | N/A | +4.2% | +7.9% (15yr)7 analysts |
| EBIT | N/A | N/A | -8.9% | +7.7% (15yr)7 analysts |
Analysis
Recent growth has been strongest in EPS at +12.2% over three years. Forward estimates point to Net Income at +7.9% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Amgen Inc.
NASDAQ:AMGN
$190.80B
Thermo Fisher Scientific Inc.
NYSE:TMO
$174.33B
Gilead Sciences, Inc.
NASDAQ:GILD
$155.36B
Pfizer Inc.
NYSE:PFE
$149.17B
Intuitive Surgical, Inc.
NASDAQ:ISRG
$144.55B
Stryker Corporation
NYSE:SYK
$120.21B
Sanofi
NASDAQ:SNY
$106.45B
Medtronic plc
NYSE:MDT
$103.09B
McKesson Corporation
NYSE:MCK
$94.82B
Boston Scientific Corporation
NYSE:BSX
$69.83B
Who manages DHR?
Danaher Corporation (DHR) lists 11 active executives. The top listed executive is Rainer Blair, President, Chief Executive Officer & Director.
Are DHR insiders buying or selling?
Recent insider activity shows net selling of $453.06M.
Explore More
Continue the stock analysis
Jump to another research area for this company.